Advanced search
Publication Cover
HIV Clinical Trials Volume 1, 2000 - Issue 3
Submit an article Journal homepage
36
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Use of Sargramostim (rh-GM-CSF) As Adjunctive Treatment of Fluconazole-Refractory Oropharyngeal Candidiasis in Patients with AIDS: A Pilot Study

Jose A. VazquezDepartment of MedicineDivision of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan, USA.
,
Jose A. HidalgoDepartment of MedicineDivision of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan, USA.
&
Sharon De BonoDepartment of MedicineDivision of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan, USA.
Pages 23-29 | Published online: 12 Jan 2015

REFERENCES

  • Vazquez JA. Options for the management of mucosal can-didiasis in patients with AIDS and HIV infection. Pharmaco-therapy. 1999;19:76–87.
  • Coker RJ, Fisher M, Tomlinson DR. Management of my-coses associated with HIV disease. Int J STD AIDS. 1995;6:408–412.
  • Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodefi-ciency virus-infected patients. J Infect Dis. 1996;173:219–225.
  • Pitrak DL. Neutrophil deficiency and dysfunction in HIV-infected patients. Am J Health Syst Pharm. 1999;56\(suppl 5):59–520.
  • Vecchiarelli A, Monari C, Baldelli F, et al. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis. 1995;171:1448–1454.
  • Armitage JO. Emerging applications of recombinant hu-man granulocyte-macrophage colony-stimulating factor. Blood. 1998;92:491–508.
  • Richardson MD, Brownlie CED, Shankland GS. Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF-activated human neutrophils. J Med Vet Mycol. 1992;30:433–441.
  • Smith PD, Lamerson CL, Banks SM, et al. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J Infect Dis. 1990;161: 999–1005.
  • Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombi-nant granulocyte-macrophage colony-stimulating factor after autologus bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773–1778.
  • Bodey GP, Anaissie E, Guterman J, et al. Role of granulo-cyte-macrophage colony-stimulating factor as adjuvant therapy of fungal infection in patients with cancer. Clin Infect Dis. 1993;17:705–707.
  • Palau LA, Pankey GA. Resolution of rhinocerebral and disseminated mucormycosis with adjuvant administration of subcutaneous granulocyte-macrophage colony-stimu-lating factor (GM-CSF). In: Proceedings of the 37th ICAAC; 1997; Toronto, Canada. Abstract LM–55.
  • Swindells S, Kleinschmidt DR, Hayes FA. Pilot study of adjunctive GM-CSF (yeast-derived) for fluconazole-resis-tent oral candidiasis in HIV-1 infection. Infect Dis Clin Pract. 1997;6:278–280.
  • Vazquez JA, Gupta S, Villanueva A. Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Eur J Clin Microbiol Infect Dis. 1998;17:781–783.
  • Angel JB, High K, Rhame F, et al. Phase III study of granulocyte-macrophage colony-stimulating factor in ad-vanced HIV disease: Effect on infections, CD4 cell counts and HIV supression. AIDS. 2000;14:387–395.
  • Skowron G, Stein D, Drusano G, et al. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: A randomized double-blind, placebo-controlled trial. J Infect Dis. 1999;180:1064–1071.
  • National Committee for Clinical Laboratory Standards (NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast: Approved Standard. NCCLS document M27-A. Wayne, PA: NCCLS; 1997.
  • Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 2000;30:662–669.
  • Powderly WG, Gallant JE, Ghannoum MA, et al. Oropha-ryngeal candidiasis in patients with HIV: Suggested guide-lines for therapy. AIDS Res Hum Retroviruses. 1999;15:1619–1623.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.